# JAKMIP2

## Overview
JAKMIP2, or Janus kinase and microtubule interacting protein 2, is a gene that encodes a protein involved in cellular processes related to the cytoskeleton and signal transduction. The protein encoded by JAKMIP2 is categorized as a microtubule-associated protein, which suggests its role in the regulation of microtubule dynamics and cellular architecture. This gene has garnered attention due to its differential expression in various cancers, including pediatric rhabdomyosarcomas and T-cell acute lymphoblastic leukemia, indicating its potential as a diagnostic marker and therapeutic target (Laé2007Global; Vicente2015Targeted). Despite its inclusion in studies related to stomach adenocarcinoma, its precise role in this context remains to be fully elucidated (Ye2020Bioinformatics).

## Clinical Significance
JAKMIP2 has been identified as a gene with clinical significance in various cancers. In the context of pediatric rhabdomyosarcomas, particularly alveolar rhabdomyosarcomas (ARMS), JAKMIP2 is overexpressed compared to embryonal rhabdomyosarcomas (ERMS). This differential expression suggests that JAKMIP2 could serve as a diagnostic marker and a potential therapeutic target for distinguishing ARMS from ERMS (Laé2007Global).

In T-cell acute lymphoblastic leukemia (T-ALL), JAKMIP2 has been noted for its higher mutation incidence in immature T-ALL cases compared to other subtypes. This suggests a potential role in the pathogenesis of this leukemia subtype, although specific functional implications of these mutations in JAKMIP2 are not detailed (Vicente2015Targeted).

While JAKMIP2 was included in the initial selection of differentially expressed genes for a prognostic model in stomach adenocarcinoma (STAD), it was not part of the final model, indicating that its role in this cancer type may be less significant or not fully understood (Ye2020Bioinformatics). Overall, JAKMIP2's altered expression and mutation patterns in these cancers highlight its potential clinical relevance.


## References


[1. (Laé2007Global) M Laé, EH Ahn, GE Mercado, S Chuai, M Edgar, BR Pawel, A Olshen, FG Barr, and M Ladanyi. Global gene expression profiling of pax‐fkhr fusion‐positive alveolar and pax‐fkhr fusion‐negative embryonal rhabdomyosarcomas. The Journal of Pathology, 212(2):143–151, May 2007. URL: http://dx.doi.org/10.1002/path.2170, doi:10.1002/path.2170. This article has 107 citations.](https://doi.org/10.1002/path.2170)

[2. (Ye2020Bioinformatics) Zaisheng Ye, Miao Zheng, Yi Zeng, Shenghong Wei, Yi Wang, Zhitao Lin, Chen Shu, Yunqing Xie, Qiuhong Zheng, and Luchuan Chen. Bioinformatics analysis reveals an association between cancer cell stemness, gene mutations, and the immune microenvironment in stomach adenocarcinoma. Frontiers in Genetics, December 2020. URL: http://dx.doi.org/10.3389/fgene.2020.595477, doi:10.3389/fgene.2020.595477. This article has 20 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fgene.2020.595477)

[3. (Vicente2015Targeted) C. Vicente, C. Schwab, M. Broux, E. Geerdens, S. Degryse, S. Demeyer, I. Lahortiga, A. Elliott, L. Chilton, R. La Starza, C. Mecucci, P. Vandenberghe, N. Goulden, A. Vora, A. V. Moorman, J. Soulier, C. J. Harrison, E. Clappier, and J. Cools. Targeted sequencing identifies associations between il7r-jak mutations and epigenetic modulators in t-cell acute lymphoblastic leukemia. Haematologica, 100(10):1301–1310, July 2015. URL: http://dx.doi.org/10.3324/haematol.2015.130179, doi:10.3324/haematol.2015.130179. This article has 174 citations.](https://doi.org/10.3324/haematol.2015.130179)